124 related articles for article (PubMed ID: 37979367)
1. Validated extended multiplexed LC-MS/MS assay for the quantification of adagrasib and sotorasib in human plasma, together with four additional SMIs.
Kruithof PD; de Beer YM; Gulikers JL; Stolk LML; Hendriks LEL; Croes S; van Geel RMJM
J Chromatogr B Analyt Technol Biomed Life Sci; 2023 Dec; 1231():123918. PubMed ID: 37979367
[TBL] [Abstract][Full Text] [Related]
2. Development and validation of an HPLC-MS/MS method to simultaneously quantify brigatinib, lorlatinib, pralsetinib and selpercatinib in human K2-EDTA plasma.
Gulikers JL; van Veelen AJ; Sinkiewicz EMJ; de Beer YM; Slikkerveer M; Stolk LML; Tjan-Heijnen VCG; Hendriks LEL; Croes S; van Geel RMJM
Biomed Chromatogr; 2023 Jun; 37(6):e5628. PubMed ID: 36941218
[TBL] [Abstract][Full Text] [Related]
3. Validated LC-MS/MS method for simultaneous quantification of KRAS
Retmana IA; Loos NHC; Schinkel AH; Beijnen JH; Sparidans RW
J Pharm Biomed Anal; 2023 Oct; 235():115612. PubMed ID: 37557065
[TBL] [Abstract][Full Text] [Related]
4. Adagrasib Treatment After Sotorasib-Related Hepatotoxicity in Patients With
Luo J; Florez N; Donnelly A; Lou Y; Lu K; Ma PC; Spira AI; Ryan D; Husain H
JCO Precis Oncol; 2024 Apr; 8():e2300644. PubMed ID: 38579193
[TBL] [Abstract][Full Text] [Related]
5. Quantification of KRAS inhibitor sotorasib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry.
Retmana IA; Loos NHC; Schinkel AH; Beijnen JH; Sparidans RW
J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Jun; 1174():122718. PubMed ID: 33957355
[TBL] [Abstract][Full Text] [Related]
6. Validation of an LC-MS/MS method for the determination of sotorasib, a KRAS
Wong P; Akrami A; Houk B; Vuu I; James CA
Bioanalysis; 2022 Oct; 14(19):1281-1292. PubMed ID: 36473022
[No Abstract] [Full Text] [Related]
7. KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments.
Koga T; Suda K; Fujino T; Ohara S; Hamada A; Nishino M; Chiba M; Shimoji M; Takemoto T; Arita T; Gmachl M; Hofmann MH; Soh J; Mitsudomi T
J Thorac Oncol; 2021 Aug; 16(8):1321-1332. PubMed ID: 33971321
[TBL] [Abstract][Full Text] [Related]
8. Development and validation of an HPLC-MS/MS method to quantify the KRAS inhibitor adagrasib in mouse plasma and tissue-related matrices.
Retmana IA; Loos NHC; Schinkel AH; Beijnen JH; Sparidans RW
Biomed Chromatogr; 2023 Nov; 37(11):e5720. PubMed ID: 37596864
[TBL] [Abstract][Full Text] [Related]
9. Targeted Therapies for Previously "Undruggable" KRAS-Mutated Non-Small Cell Lung Cancer: A Review of Sotorasib and Adagrasib.
Mausey N; Halford Z
Ann Pharmacother; 2024 Jun; 58(6):622-635. PubMed ID: 37700573
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics, Bioavailability, and Tissue Distribution of the Kirsten Rat Sarcoma Inhibitor Adagrasib in Rats Using UPLC-MS/MS.
Lei P; Shen W; Tang H; You L; Chen G; Tang Y; Lu W
Drug Des Devel Ther; 2024; 18():1-12. PubMed ID: 38205395
[TBL] [Abstract][Full Text] [Related]
11. Method development and validation for simultaneous determination of six tyrosine kinase inhibitors and two active metabolites in human plasma/serum using UPLC-MS/MS for therapeutic drug monitoring.
Zhang M; Liu X; Chen Z; Jiang S; Wang L; Tao M; Miao L
J Pharm Biomed Anal; 2022 Mar; 211():114562. PubMed ID: 35124453
[TBL] [Abstract][Full Text] [Related]
12. A simple UPLC-MS/MS assay with a core-shell column for the determination of exemestane in human plasma for clinical application.
Ishii T; Nojiri N; Mano Y
Eur J Mass Spectrom (Chichester); 2022 Jun; 28(3-4):94-103. PubMed ID: 36128912
[TBL] [Abstract][Full Text] [Related]
13. Comparison of a newly developed high performance liquid chromatography method with diode array detection to a liquid chromatography tandem mass spectrometry method for the quantification of cabozantinib, dabrafenib, nilotinib and osimertinib in human serum - Application to therapeutic drug monitoring.
Aghai-Trommeschlaeger F; Zimmermann S; Gesierich A; Kalogirou C; Goebeler ME; Jung P; Pelzer T; Kurlbaum M; Klinker H; Isberner N; Scherf-Clavel O
Clin Biochem; 2022; 105-106():35-43. PubMed ID: 35483452
[TBL] [Abstract][Full Text] [Related]
14. Quantitative bioanalytical assay for the selective RET inhibitors selpercatinib and pralsetinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry.
Şentürk R; Wang Y; Schinkel AH; Beijnen JH; Sparidans RW
J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Jun; 1147():122131. PubMed ID: 32416592
[TBL] [Abstract][Full Text] [Related]
15. Determination of Osimertinib, Aumolertinib, and Furmonertinib in Human Plasma for Therapeutic Drug Monitoring by UPLC-MS/MS.
Li Y; Meng L; Ma Y; Li Y; Xing X; Guo C; Dong Z
Molecules; 2022 Jul; 27(14):. PubMed ID: 35889345
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous and enantiospecific quantification of primaquine and carboxyprimaquine in human plasma using liquid chromatography-tandem mass spectrometry.
Hanpithakpong W; Day NPJ; White NJ; Tarning J
Malar J; 2022 Jun; 21(1):169. PubMed ID: 35659684
[TBL] [Abstract][Full Text] [Related]
17. Development and validation of an HPLC-MS/MS method to simultaneously quantify alectinib, crizotinib, erlotinib, gefitinib and osimertinib in human plasma samples, using one assay run.
van Veelen A; van Geel R; Schoufs R; de Beer Y; Stolk LM; Hendriks LEL; Croes S
Biomed Chromatogr; 2021 Dec; 35(12):e5224. PubMed ID: 34363425
[TBL] [Abstract][Full Text] [Related]
18. Development and validation of an LC-MS/MS method for the quantification of KRAS
Retmana IA; Çelebi N; Rijmers J; Schinkel AH; Beijnen JH; Sparidans RW
J Chromatogr B Analyt Technol Biomed Life Sci; 2024 Jan; 1232():123964. PubMed ID: 38103305
[TBL] [Abstract][Full Text] [Related]
19. Development and validation of a UPLC-MS/MS method for quantification of C-005, a novel third-generation EGFR TKI, and its major metabolite in plasma: Application to its first-in-patient study.
Wang Z; Ye W; Qin Y; You H; Zhang S; Fan F; Wang Y; Zheng L
J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Jan; 1162():122475. PubMed ID: 33370688
[TBL] [Abstract][Full Text] [Related]
20. Determination of a astragaloside IV derivative LS-102 in plasma by ultra-performance liquid chromatography-tandem mass spectrometry in dog plasma and its application in a pharmacokinetic study.
Sun WX; Zhang ZF; Xie J; He Y; Cheng Y; Ding LS; Luo P; Qing LS
Phytomedicine; 2019 Feb; 53():243-251. PubMed ID: 30668404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
